PM54

Phase 1Small molecule

PPharmaMar

PM54 is one of 85 small molecule programs targeting Advanced Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MalignanciesRecruiting

Advanced Solid TumorsRecruiting

Advanced MalignanciesPreclinical

Recruiting

Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

51 2

Opdivo

Bristol-Myers Squibb

Phase 2

19 3

Fludara

Sanofi

Phase 2

16 4

Paraplatin

AAvyxa

Phase 2

32 5

Tecentriq

Roche

Phase 2

11 6

Yervoy

Bristol-Myers Squibb

Phase 2

6 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 8

Erbitux

IImclone

Phase 2

16 9

Libtayo

Regeneron

Phase 2

4 10

Sutent

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Solid Tumors

NCT05841563

Q2 2029

PreclinicalRecruiting

Advanced Malignancies

NCT07644039

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

Recruiting·PPharmaMar·Phase 1·NCT05841563·125 enrolled

Advanced Malignancies1 trial

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies

Recruiting·PPharmaMar·Preclinical·NCT07644039·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PM54. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM54 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM54. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPharmaMar

PM54

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Advanced Malignancies1 trial

References

Drug Info

Quick Facts

Related News